In the field of gene function research and drug development, the primary advantage of siRNA over small molecule inhibitors, chemical drugs and antibodies is its high specificity and high throughput screening. siRNA can optimize the position and modification mode of RNAi targeted sequence, achieve gene expression silencing for different target genes, and further develop new drugs rapidly, and its screening and development time is usually better than chemical drugs and antibody drugs.
siRNA service | ||||
Application | Suitable for preliminary screening of RNAi in various cells | Increase siRNA stability and effectively inhibit target gene expression | Ensure ultra-high performance of silencing specificity, efficiency and stability of each siRNA sequence | Can be injected directly into the animal for systemic or partial drug delivery |
Advantages
1. Using professional technical design, specially optimized sequences and modifications to ensure that siRNA can achieve more than 70% silencing effect;
2. Design and synthesize siRNA for more regions of the same mRNA to improve the success rate of silencing target genes;
3.If the silencing effect of the 3 pairs of Sirnas in the kit is less than 70% in any cell line, we will redesign and synthesize an additional 3 pairs of Sirnas for the target gene for free and give them away for control. We will judge according to the experimental data you provide [you can choose one or the other, which needs to reach 80% transfection efficiency or positive interference effect reaches 70%] and qPCR primers and original results)
Service Details
S/N | Services | Specification |
PRsi001 | siRNA regular single-target synthesis | 2.5nmol |
PRsiu002 | UHP- siRNA chemical modified single-target synthesis | 2.5nmol |
PRsit003 | siRNA regular 1/3 package synthesis | 5nmol*3 |
PRsit003 | siRNA regular 2/5 package synthesis | 5nmol*5 |
PRsit004 | siRNA regular 1/3 ready-to-use package synthesis | 5nmol*3 |
PRsit004 | siRNA regular 2/5 Ready-to-Use Package Synthesis | 5nmol*5 |
Prsiut005 | UHP-siRNA chemical modified 1/3 package synthesis | 5nmol*3 |
Prsiut005 | UHP-siRNA chemical modified 2/5 package synthesis | 5nmol*5 |
Prsiut006 | UHP-siRNA chemical modified 1/3 ready-to-use package synthesis | 5nmol*3 |
Prsiut006 | UHP-siRNA chemical modified 2/5 ready-to-use package synthesis | 5nmol*5 |